Pharmaceutical - Novo Nordisk, Pricing


Current filters:

Novo NordiskPricing

Popular Filters

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven


In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone


Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Novo Nordisk now ready to launch Tresiba in Japan, following pricing accord


Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price…

Asia-PacificDegludecDiabetesMarkets & MarketingNovo NordiskPharmaceuticalPricingTresiba

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review


Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit


The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund…

Asia-PacificDiabetesGlucaGenNovo NordiskNovoMixNovoSevenPharmaceuticalPricingRegulation

Novo Nordisk tests a new business model to improve insulin access in Kenya


As part of an official Danish state visit to Kenya, global insulin giant Novo Nordisk (NOV: N) last week…

DiabetesInsulinMarkets & MarketingNovo NordiskPharmaceuticalPricingRest of the World

Back to top